Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

A Toll-like receptor recognizes bacterial DNA

Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · see citing works

Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3

Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129 · see citing works

CpG Motifs in Bacterial DNA and Their Immune Effects

Krieg, A. Μ. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.100301.064842 · Cited by 2,570 · see citing works

Functional Role of Type I and Type II Interferons in Antiviral Defense

Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453 · see citing works

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,358 · see citing works

Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes

Rothe, J., Lesslauer, W., Loetscher, H., Lang, Y., Koebel, P., Köntgen, F., Althage, A., Zinkernagel, R. M., Steinmetz, M., & Bluethmann, H. (1993) · Nature · doi:10.1038/364798a0 · Cited by 1,246 · see citing works

Marginal Zone and B1 B Cells Unite in the Early Response against T-Independent Blood-Borne Particulate Antigens

Martin, F., Oliver, A. M., & Kearney, J. F. (2001) · Immunity · doi:10.1016/s1074-7613(01)00129-7 · Cited by 987 · see citing works

Control of Early Viral and Bacterial Distribution and Disease by Natural Antibodies

Ochsenbein, A. F., Fehr, T. H., Lutz, C., Suter, M., Brombacher, F., Hengartner, H., & Zinkernagel, R. M. (1999) · Science · doi:10.1126/science.286.5447.2156 · Cited by 911 · see citing works

A crucial role for B cells in neuroinvasive scrapie

Klein, M. A., Frigg, R., Flechsig, E., Raeber, A. J., Kalinke, U., Bluethmann, H., Bootz, F., Suter, M., Zinkernagel, R. M., & Aguzzi, A. (1997) · Nature · doi:10.1038/37789 · Cited by 490 · see citing works

Immune Cell Activation by Bacterial Cpg-DNA through Myeloid Differentiation Marker 88 and Tumor Necrosis Factor Receptor–Associated Factor (Traf)6

Häcker, H., Vabulas, R. M., Takeuchi, O., Hoshino, K., Akira, S., & Wagner, H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.595 · Cited by 466 · see citing works

Impaired Prion Replication in Spleens of Mice Lacking Functional Follicular Dendritic Cells

Montrasio, F., Frigg, R., Glatzel, M., Klein, M. A., Mackay, F., Aguzzi, A., & Weissmann, C. (2000) · Science · doi:10.1126/science.288.5469.1257 · Cited by 357 · see citing works

Prevention of Scrapie Pathogenesis by Transgenic Expression of Anti-Prion Protein Antibodies

Heppner, F. L., Musahl, C., Arrighi, I., Klein, M. A., Rülicke, T., Oesch, B., Zinkernagel, R. M., Kalinke, U., & Aguzzi, A. (2001) · Science · doi:10.1126/science.1063093 · Cited by 345 · see citing works

Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure.

Odermatt, B., Eppler, M., Leist, T. P., Hengartner, H., & Zinkernagel, R. M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.18.8252 · Cited by 231 · see citing works

Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion

Prinz, M., Heikenwälder, M. F., Junt, T., Schwarz, P., Glatzel, M., Heppner, F. L., Fu, Y., Lipp, M., & Aguzzi, A. (2003) · Nature · doi:10.1038/nature02072 · Cited by 217 · see citing works

Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie

Aucouturier, P., Geissmann, F., Damotte, D., Saborı́o, G. P., Meeker, H. C., Kascsak, R., Kascsak, R. J., Carp, R. I., & Wısnıewskı, T. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13155 · Cited by 179 · see citing works

Virus-induced Transient Bone Marrow Aplasia: Major Role of Interferon-α/β during Acute Infection with the Noncytopathic Lymphocytic Choriomeningitis Virus

Binder, D., Fehr, J., Hengartner, H., & Zinkernagel, R. M. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.517 · Cited by 178 · see citing works

Infected splenic dendritic cells are sufficient for prion transmission to the CNS in mouse scrapie

Aucouturier, P., Geissmann, F., Damotte, D., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113155 · Cited by 154 · see citing works

Prions: health scare and biological challenge

Aguzzi, A., Montrasio, F., & Kaeser, P. S. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052063 · Cited by 149 · see citing works

Immunostimulatory CpG-Oligodeoxynucleotides Cause Extramedullary Murine Hemopoiesis

Sparwasser, T. D., Hültner, L., Koch, E. S., Luz, A., Lipford, G. B., & Wagner, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2368 · Cited by 147 · see citing works

Repeated Administration of Cytosine-Phosphorothiolated Guanine-Containing Oligonucleotides Together with Peptide/Protein Immunization Results in Enhanced CTL Responses with Anti-Tumor Activity

Dávila, E., & Celis, E. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.1.539 · Cited by 143 · see citing works

CpG-Containing Oligonucleotides Are Efficient Adjuvants for Induction of Protective Antiviral Immune Responses with T-Cell Peptide Vaccines

Oxenius, A., Martinic, M. M. A., Hengartner, H., & Klenerman, P. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.4120-4126.1999 · Cited by 129 · see citing works

CpG-DNA Activates In Vivo T Cell Epitope Presenting Dendritic Cells to Trigger Protective Antiviral Cytotoxic T Cell Responses

Vabulas, R. M., Pircher, H., Lipford, G. B., Häcker, H., & Wagner, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2372 · Cited by 123 · see citing works

Critical Role for Activation of Antigen-Presenting Cells in Priming of Cytotoxic T Cell Responses After Vaccination with Virus-Like Particles

Storni, T., Lechner, F., Erdmann, I., Bächi, T., Jegerlehner, A., Dumrese, T., Kündig, T. M., Ruedl, C., & Bachmann, M. F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.6.2880 · Cited by 119 · see citing works

Polyclonal Anti-PrP Auto-antibodies Induced with Dimeric PrP Interfere Efficiently with PrPSc Propagation in Prion-infected Cells

Gilch, S., Wopfner, F., Renner‐Müller, I., Kremmer, E., Bauer, C., Wolf, E., Brem, G., Groschup, M. H., & Schätzl, H. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210723200 · Cited by 111 · see citing works

Inhibition by anti-interferon serum of lymphocytic choriomeningitis virus disease in suckling mice.

Rivière, Y., Gresser, I., Guillon, J.-C., & Tovey, M. G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.5.2135 · Cited by 96 · see citing works

Prion pathogenesis in the absence of Toll-like receptor signalling

Prinz, M., Heikenwalder, M., Schwarz, P., Takeda, K., Akira, S., & Aguzzi, A. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor731 · Cited by 85 · see citing works

Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment

Dávila, E., Velez, M. G., Heppelmann, C. J. H., & Celis, E. (2002) · Blood · doi:10.1182/blood-2002-02-0401 · Cited by 52 · see citing works

Antiviral B Cell Memory in the Absence of Mature Follicular Dendritic Cell Networks and Classical Germinal Centers in TNFR1−/− Mice

Karrer, U. W., López-Macías, C. I. R., Oxenius, A., Odermatt, B., Bachmann, M. F., Kalinke, U., Bluethmann, H., Hengartner, H., & Zinkernagel, R. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.768 · Cited by 50 · see citing works

Correlation of anti-viral B cell responses and splenic morphology with expression of B cell-specific molecules.

Fehr, T., López-Macías, C., Odermatt, B., Torres, R. M., Schubart, D. B., O'Keefe, T. L., Matthias, P., Hengartner, H., & Zinkernagel, R. (2000) · International Immunology · doi:10.1093/intimm/12.9.1275 · Cited by 23 · see citing works

CpG-DNA upregulates the major acute-phase proteins SAA and SAP

Schmidt, U. G., Wagner, H., & Miethke, T. (1999) · Cellular Microbiology · doi:10.1046/j.1462-5822.1999.00007.x · Cited by 17 · see citing works

Untitled work

Sethi, S. (2002) · doi:10.1016/s0140-6736(02)09513-2

Inferences, questions and possibilities in Toll-like receptor signalling

Beutler, B. (2004) · Nature · doi:10.1038/nature02761 · Cited by 1,458 · see citing works

Therapeutic potential of Toll-like receptor 9 activation

Krieg, A. Μ. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2059 · Cited by 1,244 · see citing works

DNA Nanotechnology-Enabled Drug Delivery Systems

Hu, Q., Li, H., Wang, L., Gu, H., & Fan, C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00663 · Cited by 1,125 · see citing works

Immunotherapeutic uses of CpG oligodeoxynucleotides

Klinman, D. M. (2004) · Nature reviews. Immunology · doi:10.1038/nri1329 · Cited by 1,007 · see citing works

Medical biofilms

Bryers, J. D. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21838 · Cited by 705 · see citing works

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909

Speiser, D. E., Líénard, D., Rufer, N., Rubio‐Godoy, V., Rimoldi, D., Lejeune, F. J., Krieg, A. Μ., Cerottini, J., & Romero, P. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23373 · Cited by 637 · see citing works

Redirecting <i>In vivo</i> Elicited Tumor Infiltrating Macrophages and Dendritic Cells towards Tumor Rejection

Guiducci, C., Vicari, A. P., Sangaletti, S., Trinchieri, G., & Colombo, M. P. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4262 · Cited by 549 · see citing works

Mammalian Prion Biology

Aguzzi, A., & Polymenidou, M. (2004) · Cell · doi:10.1016/s0092-8674(03)01031-6 · Cited by 548 · see citing works

Prions: Protein Aggregation and Infectious Diseases

Aguzzi, A., & Calella, A. M. (2009) · Physiological Reviews · doi:10.1152/physrev.00006.2009 · Cited by 502 · see citing works

Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models

Takahashi, N., Duprez, L., Grootjans, S., Cauwels, A., Nerinckx, W., DuHadaway, J. B., Goossens, V, Roelandt, R., Van Hauwermeiren, F., Libert, C., et al. (2012) · Cell Death &amp; Disease · doi:10.1038/cddis.2012.176 · Cited by 465 · see citing works

Smart Drug Delivery Nanocarriers with Self‐Assembled DNA Nanostructures

Li, J., Fan, C., Pei, H., Shi, J., & Huang, Q. (2013) · Advanced Materials · doi:10.1002/adma.201300875 · Cited by 440 · see citing works

Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice

Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392 · see citing works

Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections

Mandl, J. N., Barry, A. P., Vanderford, T. H., Kozyr, N. L., Chavan, R., Klucking, S., Barrat, F. J., Coffman, R. L., Staprans, S. I., & Feinberg, M. B. (2008) · Nature Medicine · doi:10.1038/nm.1871 · Cited by 382 · see citing works

Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs

Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 376 · see citing works

Triggering TLR signaling in vaccination

van Duin, D., Medzhitov, R. M., & Shaw, A. C. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364 · see citing works

Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity

Krieg, A. Μ., & Vollmer, J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00572.x · Cited by 351 · see citing works

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

Scheiermann, J., & Klinman, D. M. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.06.065 · Cited by 323 · see citing works

Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy

Zhu, G., Lynn, G. M., Jacobson, O., Chen, K., Liu, Y., Zhang, H., Ma, Y., Zhang, F., Tian, R., Ni, Q., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02191-y · Cited by 316 · see citing works

Therapeutics targeting the innate immune system

Ulevitch, R. J. (2004) · Nature reviews. Immunology · doi:10.1038/nri1396 · Cited by 308 · see citing works

Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations

Hamdy, S. I., Haddadi, A., Hung, R., & Lavasanifar, A. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.05.021 · Cited by 297 · see citing works

Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence

Junt, T., Scandella, E., & Ludewig, B. (2008) · Nature reviews. Immunology · doi:10.1038/nri2414 · Cited by 264 · see citing works

A systematic review of prion therapeutics in experimental models

Trevitt, C. R. (2006) · Brain · doi:10.1093/brain/awl150 · Cited by 262 · see citing works

Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms

Schefold, J. C., Zeden, J.-P., Fotopoulou, C., von Haehling, S., Pschowski, R., Hasper, D., Volk, H., Schuett, C., & Reinke, P. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn739 · Cited by 256 · see citing works

TLRs Govern Neutrophil Activity in Aspergillosis

Bellocchio, S., Moretti, S., Perruccio, K., Fallarino, F., Bozza, S., Montagnoli, C., Mosci, P., Lipford, G. B., Pitzurra, L., & Romani, L. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7406 · Cited by 243 · see citing works

Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients

Martínez-Martínez, R. E., Abud‐Mendoza, C., Patiño‐Marín, N., Rodriguez, J. C. R., Little, J. W., & Loyola-Rodríguez, J. P. (2009) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2009.01496.x · Cited by 236 · see citing works

Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens

Wegmann, F., Gartlan, K. H., Harandi, A. M., Brinckmann, S., Coccia, M., Hillson, W. R., Kok, W. L., Cole, S., Ho, L., Lambe, T., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2344 · Cited by 234 · see citing works

Superior induction of anti‐tumor CTL immunity by extended peptide vaccines involves prolonged, DC‐focused antigen presentation

Bijker, M. S., van den Eeden, S. J. F., Franken, K. L. M. C., Melief, C. J. M., van der Burg, S. H., & Offringa, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200737995 · Cited by 231 · see citing works

Viral Double-Stranded RNA Aggravates Lupus Nephritis through Toll-Like Receptor 3 on Glomerular Mesangial Cells and Antigen-Presenting Cells

Patole, P. S., Gröne, H., Segerer, S., Ciubar, R., Belemezova, E., Henger, A., Kretzler, M., Diaeresis]ndorff, D. S., & Anders, H. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100820 · Cited by 221 · see citing works

Mammalian Toll-like receptors: to immunity and beyond

Hopkins, P. A., & Sriskandan, S. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02801.x · Cited by 220 · see citing works

Biodegradable CpG DNA hydrogels for sustained delivery of doxorubicin and immunostimulatory signals in tumor-bearing mice

Nishikawa, M., Mizuno, Y., Mohri, K., Matsuoka, N., Rattanakiat, S., Takahashi, Y., Funabashi, H., Luo, D., & Takakura, Y. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.013 · Cited by 219 · see citing works

Signaling in B cells via Toll-like receptors

Peng, S. L. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.03.003 · Cited by 209 · see citing works

Pathogenesis of prion diseases: current status and future outlook

Aguzzi, A., & Heikenwalder, M. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1492 · Cited by 207 · see citing works

Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders

Brisse, E., Wouters, C. H., & Matthys, P. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.001 · Cited by 206 · see citing works

Synovial inflammation in active rheumatoid arthritis and psoriatic arthritis facilitates trapping of a variety of oral bacterial DNAs.

Moen, K., Brun, J. G., Valen, M., Skartveit, L., Eribe, E. R. K., Olsen, I., & Jonsson, R. (2006) · PubMed · Cited by 206 · see citing works

Chronic innate immune activation as a cause of HIV-1 immunopathogenesis

Boasso, A., & Shearer, G. M. (2007) · Clinical Immunology · doi:10.1016/j.clim.2007.08.015 · Cited by 204 · see citing works

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system

Hanagata, N. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30197 · Cited by 199 · see citing works

Toll‐like receptor‐dependent activation of several human blood cell types by protamine‐condensed mRNA

Scheel, B., Teufel, R., Probst, J., Carralot, J., Geginat, J., Radsak, M. P., Jarrossay, D., Wagner, H., Jung, G., Rammensee, H., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200425656 · Cited by 198 · see citing works

Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice

Horikawa, M., Minard‐Colin, V., Matsushita, T., & Tedder, T. F. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59266 · Cited by 190 · see citing works

Innate immune recognition and activation during HIV infection

Mogensen, T. H., Melchjorsen, J., Larsen, C. S., & Paludan, S. R. (2010) · Retrovirology · doi:10.1186/1742-4690-7-54 · Cited by 184 · see citing works

Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist

Krieg, A. Μ., Efler, S. M., Wittpoth, M., Adhami, M. J. A., & Davis, H. L. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00006 · Cited by 183 · see citing works

Pattern recognition receptors: A contemporary view on liver diseases

Szabó, G., Dolganiuc, A., & Mandrekar, P. (2006) · Hepatology · doi:10.1002/hep.21308 · Cited by 182 · see citing works

Cellular processing and destinies of artificial DNA nanostructures

Lee, D. S., Qian, H., Tay, C. Y., & Leong, D. T. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00700c · Cited by 175 · see citing works

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 174 · see citing works

TCR ζ Down-Regulation under Chronic Inflammation Is Mediated by Myeloid Suppressor Cells Differentially Distributed between Various Lymphatic Organs

Ezernitchi, A. V., Vaknin, I., Cohen‐Daniel, L., Levy, O., Manaster, E., Halabi, A., Pikarsky, E., Shapira, L., & Baniyash, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4763 · Cited by 170 · see citing works

Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunotherapy

Huang, Z. D., Zhang, Z., Jiang, Y., Zhang, D., Chen, J., Dong, L., & Zhang, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.013 · Cited by 169 · see citing works

Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO

Wingender, G., Garbi, N., Schumak, B., Jüngerkes, F., Endl, E., von Bubnoff, D., Steitz, J., Striegler, J., Moldenhauer, G., Tüting, T., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200535602 · Cited by 169 · see citing works

Role of TLR9 in Anti-Nucleosome and Anti-DNA Antibody Production in <i>lpr</i> Mutation-Induced Murine Lupus

Lartigue, A., Courville, P., Auquit, I., François, A., Arnoult, C., Tron, F., Gilbert, D., & Musette, P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1349 · Cited by 165 · see citing works

BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation

Eckl‐Dorna, J., & Batista, F. D. (2009) · Blood · doi:10.1182/blood-2008-10-185421 · Cited by 164 · see citing works

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease

Mifsud, E. J., Tan, A. C. L., & Jackson, D. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00079 · Cited by 160 · see citing works

Gold Nanoparticle Delivery of Modified CpG Stimulates Macrophages and Inhibits Tumor Growth for Enhanced Immunotherapy

Lin, A. Y., Almeida, J. P. M., Bear, A. S., Liu, N., Luo, L., Foster, A. E., & Drezek, R. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063550 · Cited by 155 · see citing works

Targeting CpG Oligonucleotides to the Lymph Node by Nanoparticles Elicits Efficient Antitumoral Immunity

Bourquin, C., Anz, D., Zwiorek, K., Lanz, A.-L., Fuchs, S. P., Weigel, S., Wurzenberger, C., von der Borch, P., Golić, M., Moder, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.5.2990 · Cited by 152 · see citing works

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β–inducible gene expression, without significant toxicity

Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P. W., Fisher, D. C., Nadler, L. M., Coffman, R. L., & Freedman, A. S. (2004) · Blood · doi:10.1182/blood-2004-06-2156 · Cited by 151 · see citing works

The immunobiology of prion diseases

Aguzzi, A., Nuvolone, M., & Zhu, C. (2013) · Nature reviews. Immunology · doi:10.1038/nri3553 · Cited by 146 · see citing works

The critical role of type‐1 innate and acquired immunity in tumor immunotherapy

Ikeda, H., Chamoto, K., Tsuji, T., Suzuki, Y., Wakita, D., Takeshima, T., & Nishimura, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03248.x · Cited by 145 · see citing works

CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies

Hanagata, N. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s114477 · Cited by 140 · see citing works

Toll‐Like Receptor (TLR)–3, but Not TLR4, Agonist Protects against Genital Herpes Infection in the Absence of Inflammation Seen with CpG DNA

Ashkar, A. A., Yao, X.-D., Gill, N., Sajic, D., Patrick, A., & Rosenthal, K. L. (2004) · The Journal of Infectious Diseases · doi:10.1086/425079 · Cited by 138 · see citing works

Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L

Bodogai, M., Lee-Chang, C., Wejksza, K., Lai, J., Merino, M. J., Wersto, R. P., Gress, R. E., Chan, A. C., Hesdorffer, C., & Biragyn, A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4184 · Cited by 137 · see citing works

CpG Oligonucleotides as Vaccine Adjuvants

Kayraklioglu, N., Horuluoglu, B., & Klinman, D. M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_4 · Cited by 135 · see citing works

High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9–TRIF pathway

Volpi, C., Fallarino, F., Pallotta, M. T., Bianchi, R., Vacca, C., Belladonna, M. L., Orabona, C., LUCA, A. D., Boon, L., Romani, L. R., et al. (2013) · Nature Communications · doi:10.1038/ncomms2874 · Cited by 126 · see citing works

Sensor molecules in intestinal innate immunity against bacterial infections

Eckmann, L. (2006) · Current Opinion in Gastroenterology · doi:10.1097/01.mog.0000208458.38772.2a · Cited by 124 · see citing works

HIV-Induced Type I Interferon and Tryptophan Catabolism Drive T Cell Dysfunction Despite Phenotypic Activation

Boasso, A., Hardy, A. W., Anderson, S. A., Dolan, M. J., & Shearer, G. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002961 · Cited by 123 · see citing works

Microglia in prion diseases

Aguzzi, A., & Zhu, C. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90605 · Cited by 122 · see citing works

Liposome-Encapsulated CpG Oligodeoxynucleotides as a Potent Adjuvant for Inducing Type 1 Innate Immunity

Suzuki, Y., Wakita, D., Chamoto, K., Narita, Y., Tsuji, T., Takeshima, T., Gyobu, H., Kawarada, Y., Kondo, S., Akira, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1691 · Cited by 122 · see citing works

TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis

Demento, S. L., Bonafé, N., Cui, W., Kaech, S. M., Caplan, M. J., Fikrig, E., Ledizet, M., & Fahmy, T. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000768 · Cited by 120 · see citing works

Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis

Aguzzi, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03909.x · Cited by 114 · see citing works

Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival

Karbach, J., Gnjatic, S., Bender, A., Neumann, A., Weidmann, E., Yuan, J. D., Ferrara, C. A., Hoffmann, E. W., Old, L. J., Altorki, N. K., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24850 · Cited by 111 · see citing works

Accessing the therapeutic potential of immunostimulatory nucleic acids

Barchet, W., Wimmenauer, V., Schlee, M., & Hartmann, G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.07.007 · Cited by 109 · see citing works

CpG Oligodeoxynucleotides Adsorbed onto Polylactide-Co-Glycolide Microparticles Improve the Immunogenicity and Protective Activity of the Licensed Anthrax Vaccine

Xie, H., Gürsel, İ., Ivins, B. E., Singh, M., O’Hagan, D. T., Ulmer, J. B., & Klinman, D. M. (2005) · Infection and Immunity · doi:10.1128/iai.73.2.828-833.2005 · Cited by 109 · see citing works

Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA

Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H., Weller, M., & Pascolo, S. (2006) · European Journal of Immunology · doi:10.1002/eji.200635910 · Cited by 108 · see citing works

Elimination of chronic viral infection by blocking CD27 signaling

Matter, M. S., Odermatt, B., Yagita∥, H., Nuoffer, J., & Ochsenbein, A. F. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060651 · Cited by 108 · see citing works

Plasmacytoid Dendritic Cells Suppress HIV-1 Replication but Contribute to HIV-1 Induced Immunopathogenesis in Humanized Mice

Li, G., Cheng, M., Nunoya, J.-I., Cheng, L., Guo, H., Yu, H., Liu, Y.-J., Su, L., & Zhang, L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004291 · Cited by 106 · see citing works

Silica Nanoparticle as a Lymph Node Targeting Platform for Vaccine Delivery

An, M., Li, M. C., Xi, J., & Liu, H. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06024 · Cited by 106 · see citing works

The role of the innate immune response in autoimmune disease

Lang, K. S., Burow, A., Kurrer, M. O., Lang, P. A., & Recher, M. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.07.018 · Cited by 106 · see citing works

Amyloid beta peptide 1–40 enhances the action of Toll‐like receptor‐2 and ‐4 agonists but antagonizes Toll‐like receptor‐9‐induced inflammation in primary mouse microglial cell cultures

Lotz, M., Ebert, S., Esselmann, H., Iliev, A. I., Prinz, M., Wiazewicz, N., Wiltfang, J., Gerber, J., & Nau, R. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03188.x · Cited by 105 · see citing works

NGF steers microglia toward a neuroprotective phenotype

Rizzi, C., Tiberi, A., Giustizieri, M., Marrone, M. C., Gobbo, F., Carucci, N. M., Meli, G., Arisi, I., D’Onofrio, M., Marinelli, S., et al. (2018) · Glia · doi:10.1002/glia.23312 · Cited by 103 · see citing works

DNA Vaccine

Cui, Z. (2005) · Advances in genetics · doi:10.1016/s0065-2660(05)54011-2 · Cited by 102 · see citing works

Use of CpG oligodeoxynucleotides as immunoprotective agents

Klinman, D. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.937 · Cited by 100 · see citing works

Ligands to Nucleic Acid–Specific Toll-Like Receptors and the Onset of Lupus Nephritis

Pawar, R. D., Patole, P. S., Ellwart, A., Lech, M., Segerer, S., Schlöndorff, D., & Anders, H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006030263 · Cited by 99 · see citing works

A common pathway mediated through Toll-like receptors leads to T- and natural killer–cell immunosuppression

Vaknin, I., Blinder, L., Wang, L., Gazit, R., Shapira, E., Genina, O., Pines, M., Pikarsky, E., & Baniyash, M. (2007) · Blood · doi:10.1182/blood-2007-07-100404 · Cited by 98 · see citing works

Potent Antiscrapie Activities of Degenerate Phosphorothioate Oligonucleotides

Kocisko, D. A., Vaillant, A., Lee, K. S., Arnold, K. M., Bertholet, N., Race, R., Olsen, E. A., Juteau, J., & Caughey, B. W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.3.1034-1044.2006 · Cited by 98 · see citing works

Alternative vaccine delivery methods

Weniger, B. G., & Papania, M. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-0090-5.00063-x · Cited by 98 · see citing works

Prospects of vaccines for medically important fungi† A vaccine against coccidioidomycosis is justified and attainable

Cole, G. T., Xue, J., Okeke, C. N., Tarcha, E. J., Basrur, V., Schaller, R. A., Herr, R. A., Yu, J., & Hung, C.-Y. (2004) · Medical Mycology · doi:10.1080/13693780410001687349 · Cited by 97 · see citing works

Th1/Th2 cells in inflammatory disease states: therapeutic implications

Moss, R. B., Moll, T., El-Kalay, M., Kohne, C., Hoo, W. S., Encinas, J. A., & Carlo, D. J. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.12.1887 · Cited by 96 · see citing works

G-Rich DNA Suppresses Systemic Lupus

Patole, P. S., Zecher, D., Pawar, R. D., Gröne, H., Diaeresis]ndorff, D. S., & Anders, H. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060658 · Cited by 96 · see citing works

Route of Administration of the TLR9 Agonist CpG Critically Determines the Efficacy of Cancer Immunotherapy in Mice

Nierkens, S., den Brok, M. H., Roelofsen, T., Wagenaars, J. A. L., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008368 · Cited by 95 · see citing works

Novel Plant Virus-Based Vaccine Induces Protective Cytotoxic T-Lymphocyte-Mediated Antiviral Immunity through Dendritic Cell Maturation

Lacasse, P., Denis, J., Lapointe, R., Leclerc, D., & Lamarre, A. (2007) · Journal of Virology · doi:10.1128/jvi.01811-07 · Cited by 92 · see citing works

CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols

Seo, J. W., Tavaré, R., Mahakian, L. M., Silvestrini, M. T., Tam, S. M., Ingham, E. S., Salazar, F. B., Borowsky, A. D., Wu, A. M., & Ferrara, K. W. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0261 · Cited by 91 · see citing works

Role of pancreatic β ‐cell death and inflammation in diabetes

Quan, W., Jo, E., & Lee, M. ‐. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12153 · Cited by 90 · see citing works

Approaches to Therapy of Prion Diseases

Weissmann, C., & Aguzzi, A. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.56.062404.172936 · Cited by 90 · see citing works

Intralymphatic immunotherapy

Senti, G., Johansen, P., & Kündig, T. M. (2009) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e3283310ff7 · Cited by 86 · see citing works

Reaching the Threshold: A Multilayer Pathogenesis of Macrophage Activation Syndrome

Strippoli, R., Caiello, I., & Benedetti, F. D. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.121233 · Cited by 85 · see citing works

The Protein Corona as a Confounding Variable of Nanoparticle-Mediated Targeted Vaccine Delivery

Bros, M., Nuhn, L., Simon, J., Moll, L., Mailänder, V., Landfester, K., & Grabbe, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01760 · Cited by 84 · see citing works

Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits

Scholtzova, H., Do, E., Dhakal, S., Sun, Y., Liu, S., Mehta, P. D., & Wisniewski, T. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1967-16.2016 · Cited by 82 · see citing works

Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation

Jurk, M., & Vollmer, J. (2007) · BioDrugs · doi:10.2165/00063030-200721060-00006 · Cited by 81 · see citing works

Induction of CD4+ T-cell anergy and apoptosis by activated human B cells

Tretter, T., Venigalla, R. K., Eckstein, V., Saffrich, R., Sertel, S., Ho, A. D., & Lorenz, H. (2008) · Blood · doi:10.1182/blood-2008-02-140087 · Cited by 80 · see citing works

Plasmacytoid Dendritic Cells in HIV Infection

O’Brien, M. P., Manches, O., & Bhardwaj, N. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4433-6_3 · Cited by 78 · see citing works

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

Wittig, B., Schmidt, M., Scheithauer, W., & Schmoll, H. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.12.002 · Cited by 78 · see citing works

An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma

Jacobs, C., Duewell, P., Heckelsmiller, K., Wei, J., Bauernfeind, F. G., Ellermeier, J., Kisser, U., Bauer, C. A., Dauer, M., Eigler, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25399 · Cited by 78 · see citing works

Antibody-Antigen-Adjuvant Conjugates Enable Co-Delivery of Antigen and Adjuvant to Dendritic Cells in Cis but Only Have Partial Targeting Specificity

Kreutz, M., Giquel, B., Hu, Q., Abuknesha, R., Uematsu, S., Akira, S., Nestle, F. O., & Diebold, S. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040208 · Cited by 78 · see citing works

TLR9 Blockade Inhibits Activation of Diabetogenic CD8+ T Cells and Delays Autoimmune Diabetes

Zhang, Y., Lee, A. S., Shameli, A., Geng, X., Finegood, D. T., Santamaría, P., & Dutz, J. P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901814 · Cited by 78 · see citing works

Systemic application of CpG‐rich DNA suppresses adaptive T cell immunity via induction of IDO

Wingender, G., Garbi, N., Schumak, B., Jüngerkes, F., Endl, E., von Bubnoff, D., Steitz, J., Striegler, J., Moldenhauer, G., Tüting, T., et al. (2005) · European Journal of Immunology · doi:10.1002/eji.200535602 · Cited by 169 · see citing works

The roles of CpG ODN on T lymphocyte activation and suppression

Meng, M., & 孟民杰 (2007) · International Journal of Immunology · doi:10.3760/cma.j.issn.1673-4394.2007.06.017

Repeated Administration of Synthetic Oligodeoxynucleotides Expressing CpG Motifs Provides Long-Term Protection against Bacterial Infection

Klinman, D. M., Conover, J., & Coban, C. (1999) · Infection and Immunity · doi:10.1128/iai.67.11.5658-5663.1999 · Cited by 163 · see citing works

Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration

von Beust, B. R., Johansen, P., Smith, K. A., Bot, A. I., Storni, T., & Kündig, T. M. (2005) · European Journal of Immunology · doi:10.1002/eji.200526124 · Cited by 71 · see citing works

Use of CpG oligodeoxynucleotides as immunoprotective agents

Klinman, D. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.937 · Cited by 100 · see citing works